Can trazodone cause gynaecomastia? This is a question raised by some patients and clinicians, given that trazodone — a serotonin antagonist and reuptake inhibitor (SARI) licensed in the UK for depression — carries a broad side effect profile. Gynaecomastia, the enlargement of glandular breast tissue in males, arises from an imbalance between oestrogen and androgen activity. Whilst certain drug classes are well-established causes, trazodone does not significantly elevate prolactin and is not listed in its UK Summary of Product Characteristics as causing gynaecomastia. This article explores the evidence, clinical context, and what to do if you notice breast changes whilst taking trazodone.

Trazodone and Gynaecomastia: Is There a Link?

Gynaecomastia is not listed as a recognised adverse effect of trazodone in the UK SmPC or BNF; trazodone lacks dopamine-antagonist activity and does not significantly raise prolactin, making a causal link biologically implausible but not impossible.

Trazodone is an antidepressant belonging to the serotonin antagonist and reuptake inhibitor (SARI) class of medicines. In the UK, it is licensed for the treatment of depression (which may be accompanied by anxiety symptoms). Use for insomnia as a standalone indication is off-label in the UK; prescribers should be aware of this distinction. Like all medicines, trazodone carries a profile of potential side effects, and questions are sometimes raised about whether it can cause gynaecomastia — the enlargement of glandular breast tissue in males.

Gynaecomastia arises from an imbalance between oestrogen and androgen activity in breast tissue, leading to glandular proliferation. This imbalance can be driven by several mechanisms, including elevated prolactin, reduced androgen levels, increased oestrogen activity, or direct stimulation of oestrogen receptors. Several drug classes are well-established contributors, including antiandrogens, spironolactone, finasteride and dutasteride, cimetidine, ketoconazole, digoxin, and anabolic steroids.

Trazodone's mechanism of action involves blockade of serotonin receptors (particularly 5-HT2) and inhibition of serotonin reuptake, with additional alpha-adrenergic and histamine receptor antagonism. These actions do not directly elevate prolactin — a key hormonal driver of drug-induced gynaecomastia — in the way that dopamine-blocking agents (principally antipsychotics) do, and trazodone does not have clinically significant dopamine-antagonist activity.

The UK Summary of Product Characteristics (SmPC) for trazodone, as listed on the Electronic Medicines Compendium (emc), does not include gynaecomastia as a recognised adverse effect, and this is consistent with the BNF monograph for trazodone. However, SmPC wording may vary slightly across generic products, and the absence of a formal listing does not mean individual cases cannot occur. Isolated case reports exist, and a patient's concern should not be dismissed on this basis alone. Any new or unexplained breast tissue change in a male patient taking trazodone warrants clinical assessment to exclude other causes, including hormonal imbalances, concurrent medications, or underlying conditions. It is also important to distinguish true gynaecomastia (glandular tissue proliferation) from pseudogynecomastia (fatty tissue deposition), as the two have different causes and management pathways.

How Common Is Gynaecomastia With Antidepressants?

Antidepressants are not a primary cause of gynaecomastia; antipsychotics are the main psychotropic culprits via dopamine blockade and hyperprolactinaemia, whilst trazodone-related cases, if they occur, are likely rare and idiosyncratic.

Drug-induced gynaecomastia is a recognised, though relatively uncommon, adverse effect associated with certain medicines. Among psychotropic drugs, antipsychotics are the principal agents implicated via dopamine receptor blockade, which raises prolactin levels and can stimulate breast tissue growth. Antidepressants are not dopamine antagonists and are not a primary cause of hyperprolactinaemia.

Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and sertraline have been associated with gynaecomastia in rare case reports, likely through indirect or idiosyncratic hormonal mechanisms rather than a direct pharmacological effect. Tricyclic antidepressants have also been implicated occasionally in case reports. Trazodone does not significantly elevate prolactin levels, and the biological plausibility for trazodone-induced gynaecomastia is considered low. If a causal relationship exists, it is likely to be rare and may reflect individual susceptibility rather than a direct pharmacological mechanism.

Well-established non-antidepressant drug causes of gynaecomastia include:

• Antiandrogens and 5-alpha reductase inhibitors (e.g., finasteride, dutasteride, bicalutamide)

• Spironolactone (aldosterone antagonist)

• Cimetidine (H2-receptor antagonist)

• Ketoconazole (antifungal)

• Digoxin (cardiac glycoside)

• Anabolic steroids and exogenous androgens

• Certain antipsychotics (via dopamine blockade and hyperprolactinaemia)

It is worth noting that:

• Polypharmacy is common in patients taking antidepressants, and a concurrent medicine may be the actual causative agent.

• Underlying medical conditions such as hypogonadism, liver disease, chronic kidney disease (CKD), hyperthyroidism, or testicular tumours can independently cause gynaecomastia and must be excluded.

• Recreational substances, including cannabis and alcohol, are also recognised contributors.

Estimating the true incidence of antidepressant-related gynaecomastia is difficult because many cases go unreported or are attributed to other causes. Clinicians should take a thorough medication and lifestyle history before attributing breast changes to any single drug. Authoritative UK guidance on the assessment and causes of gynaecomastia is available from NICE Clinical Knowledge Summaries (CKS): Gynaecomastia, and the NHS patient information pages on gynaecomastia.

When to Speak to a GP or Pharmacist

Seek prompt GP assessment for any new breast swelling, lump, nipple discharge, or skin change; men aged 50 and over with a unilateral hard subareolar mass should be referred urgently under the NICE NG12 two-week wait pathway.

If you are taking trazodone and notice any changes in your breast tissue — such as swelling, tenderness, a lump, or nipple discharge — it is important to seek medical advice promptly. Whilst these symptoms often have a benign explanation, they should always be assessed by a healthcare professional to exclude serious underlying causes.

You should contact your GP if you experience:

• Noticeable swelling or enlargement of one or both breasts

• Breast tenderness or pain that is new or unexplained

• A firm lump beneath the nipple area

• Any nipple discharge (particularly if bloody or spontaneous)

• Nipple retraction, skin tethering, or ulceration

• Swollen lymph nodes in the armpit

Do not wait two to three weeks if you have a new breast lump, nipple discharge, or any of the features listed above — seek a GP appointment promptly. In particular, in line with NICE NG12 (Suspected Cancer: Recognition and Referral), men aged 50 and over who present with a unilateral, hard, subareolar mass — with or without skin or nipple changes — should be considered for an urgent suspected cancer referral (two-week wait pathway) to exclude male breast cancer. This applies regardless of whether a medicine is thought to be the cause.

A pharmacist can also be a helpful first point of contact. They can review your full medication list — including over-the-counter medicines and supplements — to identify any other agents that may be contributing to breast changes. However, do not stop taking your antidepressant without medical guidance, as abrupt discontinuation can cause withdrawal symptoms and a return of depressive symptoms.

Your GP may arrange a clinical examination (including testicular examination where a hormonal cause is suspected) and blood tests, which may include:

• Testosterone, oestradiol, LH, FSH, and prolactin (sex hormone profile)

• Thyroid function (TSH)

• Liver function tests (LFTs) and renal function (U&Es)

• Human chorionic gonadotrophin (hCG) to exclude a germ cell tumour

Depending on findings, breast imaging (ultrasound with or without mammography) and testicular ultrasound may also be arranged. In some cases, referral to an endocrinologist or breast clinic will be appropriate. Early assessment is particularly important if the breast change is unilateral, rapidly growing, hard, or accompanied by other systemic symptoms.

Managing Side Effects and Reviewing Your Medication

Management involves a structured medication review to identify the likely causative agent, and if trazodone is implicated, a gradual supervised switch to an alternative antidepressant following NICE NG222 guidance may be considered.

If a suspected link between trazodone and gynaecomastia is identified following clinical assessment, your GP will weigh the benefits of continuing the medication against the impact of the side effect. This is a shared decision-making process that takes into account the severity of your depression, your response to trazodone, and the degree of physical or psychological distress caused by the breast changes.

Experiencing these side effects? Our pharmacists can help you navigate them →

In many cases, a structured medication review will be the first step. This involves:

• Identifying all current medicines, including prescribed drugs, over-the-counter products, herbal remedies, and supplements

• Assessing the temporal relationship — did the gynaecomastia begin or worsen after starting trazodone, or after a dose increase?

• Considering alternative antidepressants if trazodone is deemed the likely cause and the side effect is clinically significant

If a switch to an alternative antidepressant is considered appropriate, this should be done gradually and under medical supervision, following NICE guidance on managing depression (NG222). A planned taper or cross-taper reduces the risk of discontinuation symptoms and depressive relapse; specialist input may be warranted if there is a complex psychiatric history or high relapse risk. Alternative antidepressants such as SSRIs or SNRIs may be considered, though each carries its own side effect profile and the choice should be individualised.

For mild gynaecomastia that is not causing significant distress, a watchful waiting approach may be appropriate. Drug-induced gynaecomastia often improves within several months of stopping the causative agent, though this is not guaranteed. Changes that have been present for more than 12 months may become fibrotic and are less likely to resolve spontaneously, even after the causative medicine is withdrawn.

In persistent or painful cases, specialist referral to an endocrinologist is appropriate. Specialists may consider medical therapy — for example, a short supervised course of tamoxifen — for painful or persistent gynaecomastia that has not resolved after addressing the underlying cause. Surgical options (subcutaneous mastectomy) may be considered for established fibrotic gynaecomastia causing significant distress. NICE CKS: Gynaecomastia provides further guidance on management options.

MHRA Guidance and Reporting Suspected Side Effects

Suspected adverse reactions to trazodone, including gynaecomastia, should be reported to the MHRA via the Yellow Card scheme online, by app, or via a paper form in the BNF.

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK body responsible for monitoring the safety of medicines and medical devices. The MHRA continuously reviews post-marketing safety data to identify new or emerging adverse effects that may not have been apparent during clinical trials. If you or a healthcare professional suspects that trazodone — or any other medicine — has caused an adverse reaction such as gynaecomastia, this should be reported through the Yellow Card scheme.

The Yellow Card scheme allows both patients and healthcare professionals to report suspected side effects directly to the MHRA. Reports can be submitted:

• Online at yellowcard.mhra.gov.uk

• Via the Yellow Card app, available on iOS and Android

• Through a paper Yellow Card, available in the back of the British National Formulary (BNF)

Reporting suspected side effects is important even when you are not certain that the medicine caused the reaction. The MHRA uses these reports to identify patterns and, where necessary, update prescribing information or issue safety communications to healthcare professionals. This process helps protect future patients.

Currently, the UK emc SmPC for trazodone and the BNF monograph do not list gynaecomastia as a confirmed adverse effect. Wording may vary slightly across generic trazodone products, so it is worth checking the SmPC for the specific product prescribed. The absence of a formal listing does not mean that individual cases cannot occur. Patients are encouraged to report any unexpected changes in their health whilst taking any medicine, and healthcare professionals should document suspected adverse drug reactions in patient records in line with their professional obligations and NICE safety guidance. Open communication between patients and their clinical team remains the cornerstone of safe medicines management.

Frequently Asked Questions